NDA 050742 · Merck Sharp Dohme
Stromectol
Ivermectin · Oral · Antiparasitic; Pediculicide
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Nov 22, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
221
83 Phase 3, 9 recruiting
FAERS reports
4,851
3,461 serious, 563 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 20, 2024.
INDICATIONS AND USAGE STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 22, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
2 products under this application
- STROMECTOL · IVERMECTIN 3MG · TABLET, ORAL · Discontinued · TE AB
- STROMECTOL · IVERMECTIN 6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ivermectin" as an intervention, any sponsor and status, largest first.
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical DiseasesPivotal-lookingRecruiting
Kirby InstituteGovernment (non-federal)
NCT07145736 · 52,000 participants (planned) · Start Aug 4, 2025 · Primary completion Mar 31, 2029
Drug: Moxidectin; Ivermectin · For: Onchocerciasis; Ascaris Lumbricoides Infection; Trichuris Trichiura; Infection and 2 more
Sites: Andulo, Angola
- Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)Pivotal-lookingCompleted
Barcelona Institute for Global HealthAcademic, hospital or other
NCT04966702 · 48,145 participants · Start Mar 17, 2022 · Primary completion Apr 15, 2024
Drug: Albendazole Pill; Ivermectin Pill and 1 more · For: Malaria
Sites: Kwale, Kenya; Mopeia, Mozambique
- Adjunctive Ivermectin Mass Drug Administration for Malaria ControlPivotal-lookingStatus unknown
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT04844905 · 24,000 participants (planned) · Start May 3, 2021 · Primary completion Mar 2023
Drug: Ivermectin; Placebo and 1 more · For: Malaria,Falciparum; Neglected Tropical Diseases; Strongyloidiasis and 4 more
Sites: Bissau, Guinea-Bissau
- Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic FilariasisPivotal-lookingCompleted
Washington University School of MedicineAcademic, hospital or other
NCT02899936 · 23,789 participants · Start Jul 2016 · Primary completion Apr 27, 2017
Drug: 3 drug dose - IDA; 2 drug dose - DA · For: Lymphatic Filariasis
Sites: Port-au-Prince, Haiti; Puducherry, India; Jakarta, Indonesia · 4 sites in all
- Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )Pivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT03676140 · 20,000 participants · Start Oct 1, 2018 · Primary completion Dec 15, 2018
Drug: Albendazole on Day 1; Ivermectin on Day 1 and 3 more · For: Trachoma; Yaws; Lymphatic Filariases and 2 more
Sites: Namatanai, Papua New Guinea
- Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessPivotal-lookingRecruiting
Insud PharmaIndustry
NCT06282315 · 20,000 participants (planned) · Start Sep 1, 2025 · Primary completion Apr 2026
Drug: Pre-screening Phase; Screenig Phase and 6 more · For: Soil-Transmitted Helminths
Sites: Accra, Ghana; Nairobi, Kenya
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Insecticide Resistance Management in Burkina Faso and Côte D'IvoirePivotal-lookingCompleted
Institut de Recherche pour le DeveloppementGovernment (non-federal)
NCT03074435 · 15,776 participants · Start Jul 2016 · Primary completion Aug 2018
Drug: Ivermectin · For: Malaria
Sites: Bobo-Dioulasso, Burkina Faso; Bouaké, Côte d’Ivoire
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache611
- asthenia582
- pyrexia474
- off label use463
- drug ineffective450
- product use in unapproved indication415
- diarrhoea267
- ocular hyperaemia248
- coma247
- conjunctival haemorrhage237
- back pain224
- vertigo215
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 95 |
| 2005 | 63 |
| 2006 | 360 |
| 2007 | 96 |
| 2008 | 186 |
| 2009 | 84 |
| 2010 | 139 |
| 2011 | 53 |
| 2012 | 72 |
| 2013 | 92 |
| 2014 | 107 |
| 2015 | 110 |
| 2016 | 89 |
| 2017 | 110 |
| 2018 | 195 |
| 2019 | 190 |
| 2020 | 216 |
| 2021 | 467 |
| 2022 | 426 |
| 2023 | 350 |
| 2024 | 361 |
| 2025 | 555 |
| 2026 | 435 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Sep 29, 2026
STROMECTOL, Tablet, 3 mg (NDC 0006-0032-01). Product will be discontinued on 10/31/2026
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Stromectol (IVermectin)
2024 spending
$995
Beneficiaries
14
19 claims
Per beneficiary
$71
$4.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,243 |
| 2021 | $34,111 |
| 2022 | $4,324 |
| 2023 | $1,634 |
| 2024 | $995 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug.
Tang M, Hu X, Wang Y, et al. · Pharmacol Res 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Failure of scabies treatment: a systematic review and meta-analysis.
Mbuagbaw L, Sadeghirad B, Morgan RL, et al. · Br J Dermatol 2024 · Meta-Analysis, Systematic Review
- Ivermectin to Control Malaria - A Cluster-Randomized Trial.
Chaccour C, Maia M, Kariuki M, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Anthelmintic drugs for treating ascariasis.
Conterno LO, Turchi MD, Corrêa I, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trial.
Boralevi F, Simon G, Bernigaud C, et al. · BMJ 2026 · Multicenter Study, Randomized Controlled Trial
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.